Skip to main content

Table 5 Distribution of C4 polymorphisms in Graves' disease patients with or without vitiligo

From: Association between copy number variation of complement component C4 and Graves' disease

Variations

Vitiligo

P value, individuala

[OR (95%CI), individual]c

P valueb

OR (95%CI)d

 

No, N (%)

Yes, N (%)

   

C4 CNV

     

4

258 (50.6)

56 (49.1)

0.836

0.002

(Reference)

< 4

97 (19.0)

37 (32.5)

0.002 [1.297 (0.434-3.874)]

 

1.334 (0.415-4.289)

> 4

155 (30.4)

21 (18.4)

0.011 [0.987 (0.362-2.691)]

 

1.076 (0.370-3.133)

C4A CNV

     

2

330 (64.7)

65 (57.0)

0.133

 

(Reference)

< 2

52 (10.2)

27 (23.7)

2.650 × 10-4 [5.153 (1.629-16.3000]

0.001

5.579 (1.659-18.763)

> 2

128 (25.1)

22 (19.3)

0.225

 

1.289 (0.414-4.013)

C4B CNV

     

2

310 (60.8)

67 (58.8)

0.751

 

(Reference)

< 2

112 (22.0)

31 (27.2)

0.267

0.414

1.133 (0.355-3.614)

> 2

88 (17.3)

16 (14.0)

0.487

 

2.107 (0.687-6.467)

C4 polymorphisms

     

A2B2

213 (41.8)

41 (36.0)

0.292

0.03

(Reference)

A2B1

62 (12.2)

16 (14.0)

0.638

 

0.889 (0.175-4.524)

A3B2

57 (11.2)

7 (6.1)

0.125

 

0.756 (0.132-4.335)

A2B3

40 (7.8)

4 (3.5)

0.154

 

1.111 (0.151-8.205)

A3B1

25 (4.9)

7 (6.1)

0.638

 

1.484 (0.199-11.089)

A1B2

22 (4.3)

12 (10.5)

0.019 [2.035(0.335-12.368)]

 

2.745 (0.384-19.599)

Other

91 (17.8)

27 (23.7)

  

3.471 (1.046-11.525)

  1. Abbreviations: GD, Graves' disease; GO, Graves' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
  2. aIndividual C4 CNVs and polymorphisms between GD patients with or without vitiligo were evaluated by Fisher's exact test using 2 × 2 contingency tables.
  3. b CNV of C4, C4A and C4B between GD patients with or without vitiligo were evaluated by Fisher's exact test using 3 × 2 contingency tables.C4 polymorphisms between GD patients with or without vitiligo were evaluated by Fisher's exact test using 7 × 2 contingency tables. The p value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).
  4. cORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, myxedema and GO.
  5. dORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, myxedema and GO.